Lantern Pharma reports complete response in aggressive lymphoma patient

DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN), a $43.46 million market cap biotech company whose stock has gained 26.33% year-to-date, announced Wednesday that a patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase 1 clinical trial of its experimental drug LP-284. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with analyst price targets ranging from $15 to $26.

According to the company’s press release statement, the 41-year-old patient had previously failed three treatment regimens over the past 18 months, including standard chemotherapy, CAR-T cell therapy, and CD3xCD20 bispecific antibody therapy. The patient achieved complete metabolic response after completing just two 28-day cycles of LP-284. While the company maintains a strong liquidity position with a current ratio of 4.86 and more cash than debt on its balance sheet, InvestingPro data shows the company is rapidly burning through cash - a common characteristic of clinical-stage biotech firms.

LP-284 is described as a next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. The drug was developed using Lantern’s RADR artificial intelligence platform.

The patient entered the study in April 2025 with extensive multifocal bony lesions across thoracic and lumbar spine locations and hips after experiencing disease progression following previous treatments.

Lantern Pharma’s ongoing Phase 1 dose-escalation study (NCT06132503) is evaluating LP-284’s safety profile, optimal dosing parameters, and preliminary efficacy across multiple aggressive lymphoma subtypes.

The drug has received multiple Orphan Drug Designations from the U.S. Food and Drug Administration, including designations for mantle cell lymphoma and high-grade B-cell lymphomas.

Lantern Pharma plans to continue enrollment in the Phase 1 trial while monitoring the responding patient for durability of response. The company stated it will provide additional clinical updates as the trial progresses and more patients reach evaluable timepoints.

DLBCL represents the largest aggressive lymphoma subtype, affecting approximately 200,000 patients globally each year, according to the company’s statement. With the next earnings report due on August 6, 2025, investors can access comprehensive analysis and 8 additional ProTips through InvestingPro’s detailed research reports, which provide deep-dive analysis of biotech companies and their development pipelines.

In other recent news, Lantern Pharma Inc. reported a narrower net loss for the first quarter of 2025 compared to the same period last year. This improvement reflects the company’s strategic focus on cost management and innovation in drug development. Lantern Pharma has introduced a new artificial intelligence module within its RADR platform, designed to predict the efficacy of combination therapies for cancer treatment. This module was developed after analyzing data from 221 clinical trials and aims to address a growing cancer therapy market. Additionally, Lantern Pharma unveiled promising preclinical data for its drug candidate LP-184, targeting a rare pediatric brain cancer. The data showed significant improvements in median survival in mouse models, supporting the drug’s FDA Rare Pediatric Disease Designation. The company plans to begin a pediatric clinical trial for LP-184 between late 2025 and early 2026. These developments highlight Lantern Pharma’s continued advancements in clinical trials and AI-driven drug discovery.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.